This roundtable series explores tyrosine kinase inhibitor use and other treatments for patients with renal cell carcinoma, as discussed by participants at virtual live events.
Reviewing the Choice of First-Line Combinations for Clear Cell RCC and Other Histologies
July 15th 2022During a live virtual event, Ulka N. Vaishampayan, MBBS, discussed the choice of first-line therapy for clear cell renal cell carcinoma and whether the approach to treatment would change with other disease histologies.
POLL: What Frontline Treatment Would You Choose for Favorable- and Intermediate-Risk RCC?
August 29th 2022Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with previously untreated clear cell renal cell carcinoma. Vote in the polls on what you would have chosen if this was your patient.
Comparing Physician Experience With Trial Data for Frontline RCC Regimens
October 3rd 2022During a live virtual event, Sumanta K. Pal, MD, discussed with participants how their experience with immunotherapy and tyrosine kinase inhibitor therapies aligned with the data from pivotal clinical trials. This is the second of 2 articles based on this event.
Physicians Discuss Potential of Frontline Triplet Regimens for RCC
January 27th 2023During a Targeted Oncology case-based roundtable event, Alan Tan, MD, discussed with participants their experience with tyrosine kinase inhibitor/immunotherapy combinations and the most recent results of triplet trials.
Opinions on the Optimal Role of Ipilimumab/Nivolumab in RCC
February 13th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Alan Tan, MD, discussed with participants their experiences with frontline regimens for advanced renal cell carcinoma, and potential trials that could optimize the use of immunotherapy and tyrosine kinase inhibitors. This is the second of 2 articles based on this event.
Selecting IO/TKI Therapy for mRCC Based on Patient Profile
April 3rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Deepak Kilari, MD, discussed with participants their impressions of tyrosine kinase inhibitor plus immune checkpoint inhibitor trials for patients with metastatic renal cell carcinoma.
Real-World Factors Influence Choice of IO/TKI Regimen for mRCC
May 1st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Deepak Kilari, MD, discussed with participants what real-world patient conditions would impact their choice of frontline therapy for metastatic renal cell carcinoma. This is the second of 2 articles based on this event.
Risk Group Data Raises Questions on Choice of Frontline Therapy in RCC
June 8th 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Manojkumar Bupathi, MD, MS, discussed with participants how risk groups affect their choice of first-line treatment in renal cell carcinoma. This is the first of 2 articles based on this event.
Physicians Discuss Counseling on Immunotherapy Discontinuation in RCC
July 3rd 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Manojkumar Bupathi, MD, and participants discussed using immunotherapy plus tyrosine kinase inhibitor to treat advanced renal cell carcinoma. This is the second of 2 articles based on this event.
Updated Data Supports Use of Nivolumab + Cabozantinib in Advanced ccRCC
August 9th 2023In the first article of a 2-part series, Rana McKay, MD, goes through the updated data from the CheckMate 9ER trial that supports the continued use of the combination of nivolumab and cabozantinib for patients with metastatic clear cell renal cell carcinoma.
Nivolumab plus Cabozantinib Continues to Show Benefit in Advanced RCC
September 5th 2023In the second article of a 2-part series, Rana McKay, MD, discussed follow-up analyses of the phase 3 CheckMate 9ER trial that showed the benefit of nivolumab plus cabozantinib vs sunitinib for patients with advanced renal cell carcinoma.
Treatment Selection and Dosing Strategies Based on Trial Data in RCC
November 1st 2023During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, and participants discussed their takeaways from the phase 3 trials of immunotherapy and tyrosine kinase inhibitors in frontline renal cell carcinoma. This is the second article based on this event.